Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes

Masuda, Hiroko; Brewer, Takae; Liu, D. D.; Inomata, Takayuki; Shen, Yu; Hsu, Limin; Willey, Jie; González-Angulo, Ana M.; Chávez-MacGregor, Mariana; Fouad, Tamer M.; Woodward, Wendy A.; Reuben, James M.; Valero, Vicente; Álvarez, Ricardo H.; Hortobágyi, Gabriel N.; Ueno, Naoto T.

doi:10.1093/annonc/mdt525

Cited by 108 publications

(114 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in keeping with those of the NOAH trial (10), a randomized phase III trial evaluating neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer, recently updated (26) The results of BEVERLY-2 are encouraging as IBC is a rare yet aggressive form of breast cancer, and has poor prognosis (27). Chemotherapy-induced pCR rates were historically low in that setting, ranging from 20% to 30% (9,28,29). Over the past decade, clinical trials have demonstrated incremental improvements in outcome for patients with IBC.…”

Section: Discussionsupporting

confidence: 72%

“…The use of pCR as a prognostic marker for DFS and OS in patients treated by neoadjuvant therapy is supported by several lines of evidence (12,13), including recent reports in HER2-positive breast cancer (9,(14)(15)(16). A noticeable dissociation was however observed in non-IBC with bevacizumab, which increased the pCR rate in the neoadjuvant setting (17,18) but had no impact on survival in the adjuvant setting of HER2-positive breast cancer (19,20).…”

Section: Introductionmentioning

confidence: 94%

“…Despite this progress, the prognosis for women with IBC remains poor, with a median overall survival (OS) of approximately 40 to 60 months (6)(7)(8)(9). Neoadjuvant chemotherapy and trastuzumab followed by adjuvant trastuzumab is a standard of care for locally advanced HER2-positive primary breast cancer (10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Pierga

Petit²,

Lévy

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The BEVERLY-2 single-arm phase II trial assessed the efficacy and safety of combining neoadjuvant chemotherapy with bevacizumab and trastuzumab for the treatment of HER2-positive inflammatory breast cancer (IBC). Here, we report the results of a preplanned survival analysis at 3 years of follow-up, along with the association between outcome and circulating biomarkers and pathologic complete response (pCR).Experimental Design: Patients received fluorouracil, epirubicin, cyclophosphamide, and bevacizumab (cycles 1-4) and docetaxel, trastuzumab, and bevacizumab (cycles 5-8) before surgery, followed by trastuzumab and bevacizumab for 30 weeks after surgery. Circulating tumor cell (CTC) and endothelial cell (CEC) counts were assessed at baseline, cycle 5, preoperative, postoperative, and at 1 year.Results: Fifty-two patients were included. The 3-year diseasefree survival (DFS) rate was 68% and overall survival (OS) rate was 90%. pCR (centrally reviewed) was strongly associated with 3-year DFS [80% and 53% in patients with/without pCR, respectively (P ¼ 0.03)]. CTC detection also independently predicted 3-year DFS [81% vs. 43% for patients with <1 vs. !1 CTC/7.5 mL at baseline (P ¼ 0.01)]. Patients with no CTCs detected at baseline and with pCR had a high 3-year DFS (95%). CEC changes during treatment had no prognostic value.Conclusions: Our study suggests that the prognosis of IBC relies on more than the achievement of pCR and highlights the role of early hematogenous tumor dissemination as assessed by CTCs. Combining these two prognostic factors isolates a subgroup of IBC with excellent survival when treated with bevacizumab-and trastuzumabcontaining regimens.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Pierga

Petit²,

Lévy

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Although IBC comprises <5% of breast cancer cases, the tumor accounts for more than 10% of breast cancer mortality in the United States (2,3). IBC is considered aggressive because it evolves rapidly-over days to weeks rather than months-with most patients presenting with lymph node involvement and more than 30% of patients having distant metastases at diagnosis (4,5). Although IBC, like non-IBC breast cancers, is a heterogeneous disease and can occur as any of the five molecular subtypes, the IBC is most commonly ErbB2 overexpressing or triple negative (6), thus rendering a large armamentarium of targeted drugs ineffective.…”

mentioning

confidence: 99%

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes

Dobroff

D’Angelo

Eckhardt

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Inflammatory breast carcinoma (IBC) is one of the most lethal forms of human breast cancer, and effective treatment for IBC is an unmet clinical need in contemporary oncology. Tumor-targeted theranostic approaches are emerging in precision medicine, but only a few specific biomarkers are available. Here we report up-regulation of the 78-kDa glucose-regulated protein (GRP78) in two independent discovery and validation sets of specimens derived from IBC patients, suggesting translational promise for clinical applications. We show that a GRP78-binding motif displayed on either bacteriophage or adeno-associated virus/phage (AAVP) particles or loop-grafted onto a human antibody fragment specifically targets orthotopic IBC and other aggressive breast cancer models in vivo. To evaluate the theranostic value, we used GRP78-targeting AAVP particles to deliver the human Herpes simplex virus thymidine kinase type-1 (HSVtk) transgene, obtaining simultaneous in vivo diagnosis through PET imaging and tumor treatment by selective activation of the prodrug ganciclovir at tumor sites. Translation of this AAVP system is expected simultaneously to image, monitor, and treat the IBC phenotype and possibly other aggressive (e.g., invasive and/or metastatic) subtypes of breast cancer, based on the inducible cell-surface expression of the stress-response chaperone GRP78, and possibily other cell-surface receptors in human tumors.inflammatory breast cancer | ligand-directed theranostics | molecular imaging | gene therapy | AAVP B reast cancer remains a major cause of cancer death in women (1), and one of its most lethal presentations is inflammatory breast carcinoma (IBC), a clinicopathological diagnosis characterized by diffuse erythema/edema involving the skin of the breast (a sign classically known as "peau d'orange") caused by tumor emboli within the dermal lymphatics. Although IBC comprises <5% of breast cancer cases, the tumor accounts for more than 10% of breast cancer mortality in the United States (2, 3). IBC is considered aggressive because it evolves rapidly-over days to weeks rather than months-with most patients presenting with lymph node involvement and more than 30% of patients having distant metastases at diagnosis (4, 5). Although IBC, like non-IBC breast cancers, is a heterogeneous disease and can occur as any of the five molecular subtypes, the IBC is most commonly ErbB2 overexpressing or triple negative (6), thus rendering a large armamentarium of targeted drugs ineffective. Finally, IBC generally presents with high-grade histology, elevated cell proliferation rate, and angiolymphatic invasion (5, 7). Indeed, the hallmark lymphatic invasion dictates the requirement for initial systemic treatment of IBC, because micrometastatic disease likely has occurred even in the Significance Inflammatory breast cancer (IBC) is defined clinically and pathologically. Dermal lymphatic invasion is typical but is neither necessary nor sufficient for diagnosis; sentinel lymph node biopsy is contraindicated, challenging multidisciplinar...

show abstract

“…At the time of presentation, 55 to 85% of patients have regional lymph node metastasis clinically. 2 Despite improved survival in the past three decades because of the introduction of multimodality treatment approaches, the survival outcomes of patients with inflammatory breast cancer remain poorer compared with patients with noninflammatory, locally advanced breast cancer, 3,4 underscoring the need for understanding the biology of the disease and exploring new therapeutic targets.…”

mentioning

confidence: 99%

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

et al. 2016

View full text Add to dashboard Cite

Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between normal breast tissue and tumor tissue, most of them did not show differential expression between inflammatory and noninflammatory tumor samples. However, by microarray analysis, quantitative reverse transcription PCR, and in situ hybridization, we showed that microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with noninflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. A small-scale immunohistochemistry analysis showed coexistence of decreased microRNA-205 expression and decreased E-cadherin expression in some ductal tumors. MicroRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.

show abstract

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes

Cited by 108 publications

References 14 publications

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

Contact Info

Product

Resources

About